Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 3/9 cls
Anesiva (ANSV) Lazard Megan Murphy New Buy 1% $7.56
Murphy set a $10 target. She believes 4975, a non-narcotic injectable capsaicin anesthetic, will enter Phase III trials this year and is an asset with low clinical risk and significant market potential. She expects a 2008 partnership for moderate and severe osteoarthritis.
Aspreva (TSX:ASV; ASPV) Stanford Group Hanzhong Li New Buy -5% $20.99
Li set a $28 target. He believes ASV has a favorable risk/reward profile as CellCept's off-label autoimmune sales continue to grow ahead of Phase III data for lupus nephritis, which are expected in 2Q07.

Read the full 1097 word article

How to gain access

Continue reading with a
two-week free trial.